HIV in the tropics: Staging in the resource-limited setting

Julie K. Varughese, Michael G. Rosenberg, Kami Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose of Review: In 2010, the WHO updated HIV treatment guidelines for adults and children, expanding the eligibility of HIV-infected individuals for antiretroviral therapy (ART) on the basis of immunological staging. We discuss the barriers to HIV staging in under-resourced settings. Recent Findings: In industrialized countries, HIV-infected patients are immunologically staged using CD4 lymphocyte counts measured using flow cytometry, but reliable and timely CD4 testing is still not readily available for all patients in many poorly resourced countries. Often CD4 testing is only available in central hospitals and clinics and depends upon availability of reagents. This leaves clinical staging as the standard of care in many places. Significant discrepancies exist between clinical and immunologic staging. Lack of immunologic staging can lead to delayed or inappropriate initiation of ART, increased attrition before ART, and overall poorer outcomes as patients often initiate ART at lower CD4 cell count baselines. This has led to intensive efforts to develop cost-effective laboratory testing, particularly for accurate low-cost CD4 testing. Summary: Simplified, low-cost alternatives for immunologic staging are vital to continued scale up of ART programs globally. Point-of-care CD4 testing in particular has shown promise in decreasing attrition rates before ART and improving overall mortality in resource-limited settings.

Original languageEnglish (US)
Pages (from-to)477-483
Number of pages7
JournalCurrent Opinion in Infectious Diseases
Volume25
Issue number5
DOIs
StatePublished - Oct 2012

Fingerprint

HIV
CD4 Lymphocyte Count
Costs and Cost Analysis
Therapeutics
Standard of Care
Developed Countries
Flow Cytometry
Guidelines
Mortality

Keywords

  • CD4
  • clinical staging
  • HIV
  • resource limited

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

HIV in the tropics : Staging in the resource-limited setting. / Varughese, Julie K.; Rosenberg, Michael G.; Kim, Kami.

In: Current Opinion in Infectious Diseases, Vol. 25, No. 5, 10.2012, p. 477-483.

Research output: Contribution to journalArticle

Varughese, Julie K. ; Rosenberg, Michael G. ; Kim, Kami. / HIV in the tropics : Staging in the resource-limited setting. In: Current Opinion in Infectious Diseases. 2012 ; Vol. 25, No. 5. pp. 477-483.
@article{10448a8e2c4744f4937262b17352d143,
title = "HIV in the tropics: Staging in the resource-limited setting",
abstract = "Purpose of Review: In 2010, the WHO updated HIV treatment guidelines for adults and children, expanding the eligibility of HIV-infected individuals for antiretroviral therapy (ART) on the basis of immunological staging. We discuss the barriers to HIV staging in under-resourced settings. Recent Findings: In industrialized countries, HIV-infected patients are immunologically staged using CD4 lymphocyte counts measured using flow cytometry, but reliable and timely CD4 testing is still not readily available for all patients in many poorly resourced countries. Often CD4 testing is only available in central hospitals and clinics and depends upon availability of reagents. This leaves clinical staging as the standard of care in many places. Significant discrepancies exist between clinical and immunologic staging. Lack of immunologic staging can lead to delayed or inappropriate initiation of ART, increased attrition before ART, and overall poorer outcomes as patients often initiate ART at lower CD4 cell count baselines. This has led to intensive efforts to develop cost-effective laboratory testing, particularly for accurate low-cost CD4 testing. Summary: Simplified, low-cost alternatives for immunologic staging are vital to continued scale up of ART programs globally. Point-of-care CD4 testing in particular has shown promise in decreasing attrition rates before ART and improving overall mortality in resource-limited settings.",
keywords = "CD4, clinical staging, HIV, resource limited",
author = "Varughese, {Julie K.} and Rosenberg, {Michael G.} and Kami Kim",
year = "2012",
month = "10",
doi = "10.1097/QCO.0b013e3283567b00",
language = "English (US)",
volume = "25",
pages = "477--483",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - HIV in the tropics

T2 - Staging in the resource-limited setting

AU - Varughese, Julie K.

AU - Rosenberg, Michael G.

AU - Kim, Kami

PY - 2012/10

Y1 - 2012/10

N2 - Purpose of Review: In 2010, the WHO updated HIV treatment guidelines for adults and children, expanding the eligibility of HIV-infected individuals for antiretroviral therapy (ART) on the basis of immunological staging. We discuss the barriers to HIV staging in under-resourced settings. Recent Findings: In industrialized countries, HIV-infected patients are immunologically staged using CD4 lymphocyte counts measured using flow cytometry, but reliable and timely CD4 testing is still not readily available for all patients in many poorly resourced countries. Often CD4 testing is only available in central hospitals and clinics and depends upon availability of reagents. This leaves clinical staging as the standard of care in many places. Significant discrepancies exist between clinical and immunologic staging. Lack of immunologic staging can lead to delayed or inappropriate initiation of ART, increased attrition before ART, and overall poorer outcomes as patients often initiate ART at lower CD4 cell count baselines. This has led to intensive efforts to develop cost-effective laboratory testing, particularly for accurate low-cost CD4 testing. Summary: Simplified, low-cost alternatives for immunologic staging are vital to continued scale up of ART programs globally. Point-of-care CD4 testing in particular has shown promise in decreasing attrition rates before ART and improving overall mortality in resource-limited settings.

AB - Purpose of Review: In 2010, the WHO updated HIV treatment guidelines for adults and children, expanding the eligibility of HIV-infected individuals for antiretroviral therapy (ART) on the basis of immunological staging. We discuss the barriers to HIV staging in under-resourced settings. Recent Findings: In industrialized countries, HIV-infected patients are immunologically staged using CD4 lymphocyte counts measured using flow cytometry, but reliable and timely CD4 testing is still not readily available for all patients in many poorly resourced countries. Often CD4 testing is only available in central hospitals and clinics and depends upon availability of reagents. This leaves clinical staging as the standard of care in many places. Significant discrepancies exist between clinical and immunologic staging. Lack of immunologic staging can lead to delayed or inappropriate initiation of ART, increased attrition before ART, and overall poorer outcomes as patients often initiate ART at lower CD4 cell count baselines. This has led to intensive efforts to develop cost-effective laboratory testing, particularly for accurate low-cost CD4 testing. Summary: Simplified, low-cost alternatives for immunologic staging are vital to continued scale up of ART programs globally. Point-of-care CD4 testing in particular has shown promise in decreasing attrition rates before ART and improving overall mortality in resource-limited settings.

KW - CD4

KW - clinical staging

KW - HIV

KW - resource limited

UR - http://www.scopus.com/inward/record.url?scp=84865862953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865862953&partnerID=8YFLogxK

U2 - 10.1097/QCO.0b013e3283567b00

DO - 10.1097/QCO.0b013e3283567b00

M3 - Article

C2 - 22744319

AN - SCOPUS:84865862953

VL - 25

SP - 477

EP - 483

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 5

ER -